LATAM MedTech Insights – Details, episodes & analysis

This week, we dive into a sudden and seismic regulatory shift in Argentina. ANMAT's newly issued Resolution 785/2025 has introduced strict data localization and cybersecurity audit requirements for all Software as a Medical Device (SaMD) and connected devices, sending shockwaves through the industry. This episode breaks down the immediate implications for foreign manufacturers, who now face a tight 180-day deadline to overhaul their data infrastructure. We explore the strategic challenges posed by this new regulation, from the technical complexities of data migration to the uncertainty surrounding the list of approved local auditors. This is a must-listen for any MedTech company operating in or planning to enter the Argentinian market, providing a clear-eyed look at the new reality of digital protectionism in Latin America and what it takes to maintain compliance and market access. A specific case we discuss involves a leading European AI radiology software provider. Their platform relies on centralized servers in Brazil, and they now face the daunting and costly task of migrating their entire operation to a local Argentinian data center within 180 days. This unexpected mandate threatens to disrupt their services for existing hospital clients and could derail their growth strategy in the region. Key questions for this episode: - What are the exact requirements of ANMAT's new Resolution 785/2025? - How does the data localization mandate impact cloud-based SaMD and IoT devices? - What are the first three steps your company must take to assess its compliance risk? - Why are even well-established products with existing registrations in Argentina at risk? - How can you find and qualify a local data hosting partner that meets ANMAT's new stringent standards? - What specific cybersecurity documentation must be added to your technical dossier for submission? - Is this new Argentinian rule a blueprint for future regulations in other major LATAM markets? Struggling with sudden regulatory shifts in LATAM? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. From acting as your local representative in Argentina to developing a new regulatory strategy for data compliance, we ensure you maintain your market presence without disruption. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just proposed a new fast-track approval process for AI-driven medical software, promising to slash market entry timelines for devices already approved by agencies like the FDA. But a closer look reveals a complex new challenge that could catch even the most prepared companies off guard. Imagine you're a global MedTech company with an FDA-cleared diagnostic AI. You see the 'fast-track' news from Brazil and plan for a quick launch. But your planned submission is suddenly non-compliant, citing a new, demanding annex on data traceability and cybersecurity specific to the Brazilian population that your initial regulatory package never accounted for. This is the hidden reality companies will now face. What you'll learn in this episode: - What is ANVISA's new proposed fast-track for AI medical devices? - Why is the new data governance requirement a hidden barrier for foreign manufacturers? - How do these proposed Brazilian rules differ from standard FDA or Health Canada requirements? - Could this 'fast-track' pathway actually delay market entry for unprepared companies? - What immediate steps should you take to assess your AI's training data for compliance? - Which specific local data protection protocols (LGPD) are now integrated into regulatory clearance? - How can this change be leveraged to build a stronger, more defensible market position in Brazil? Don't let regulatory surprises derail your LATAM expansion. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline market access in Brazil and over 30 other markets. We help you navigate complex changes like ANVISA's new AI rules, ensuring your technical dossier is compliant from day one. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Brazil's regulatory agency, ANVISA, has just redefined the future of digital health in Latin America with its new, comprehensive framework for AI-powered Software as a Medical Device (SaMD). This landmark regulation introduces a stricter risk classification system and new requirements for algorithm validation and cybersecurity, directly impacting any MedTech company looking to enter or grow in the region's largest market. This episode of LATAM MedTech Insights provides a crucial analysis of these changes. We uncover what the new four-tiered risk system means for your product, how to manage the lifecycle of your AI algorithms under the new rules, and why aligning with Brazil's data privacy laws is now more critical than ever. This isn't just a regulatory update. it's a strategic shift that will influence the entire LATAM region. **Case Study:** Imagine your AI-powered diagnostic tool, which has been operating in a regulatory gray area, is suddenly reclassified as a high-risk device under the new ANVISA framework. You now face urgent demands for more extensive clinical data, a formal algorithm change protocol, and stricter cybersecurity measures, potentially delaying your market access by months. Are you prepared to meet this new, higher standard. **Key Takeaways:** * What are the most significant changes in ANVISA's new SaMD regulation. * How does Brazil's new AI framework compare to the FDA and EU MDR standards. * Why might your SaMD's risk classification change overnight in Brazil. * What specific cybersecurity vulnerabilities is ANVISA now targeting. * Has the Brazilian market become more challenging or more predictable for foreign SaMD companies. * How will this decision impact regulatory trends in other LATAM markets like Mexico and Colombia. * What are the immediate next steps your regulatory team must take to ensure compliance. Navigating these regulatory shifts requires local expertise and a global strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline global market access. We help you turn regulatory complexity into a competitive advantage. To secure your position in the evolving Latin American market, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we're diving into a groundbreaking regulatory shift in Brazil. For years, launching a clinical trial in Latin America's largest market was a high-risk gamble due to unpredictable and lengthy approval processes. Now, everything has changed. A new Clinical Research Statute is dismantling these old barriers, aiming to slash approval times and make Brazil a global hub for MedTech innovation. We explore the concrete changes to the ethics review system and what this means for international companies that had previously put their Brazilian market entry plans on hold. A U.S. MedTech startup with a novel cardiovascular device had to shelve its plans to enter Brazil because of the dreaded 18-month approval delays, which threatened their investment timeline. Now, the new law presents a clear, predictable path to starting their clinical trial in under six months, completely changing their strategic calculus for the LATAM region. This Episode’s Key Takeaways: - Why was Brazil’s old clinical trial system a major roadblock for MedTech innovators? - How exactly does the new Clinical Research Statute reduce approval timelines? - What is the role of the new INEP ethics board, and how does it differ from the old system? - Are the responsibilities for trial sponsors now easier to manage in Brazil? - What immediate steps should a foreign MedTech company take to leverage this new regulation? - Is Brazil poised to become the new leader for clinical research in Latin America? - What are the hidden risks or remaining challenges in this new regulatory environment? At Pure Global, we offer end-to-end regulatory consulting solutions to help MedTech and IVD companies navigate complex markets like Brazil. We combine local expertise with advanced AI and data tools to streamline global market access, from initial strategy and technical dossier submission to post-market surveillance. Let us be your local representative and strategic partner in over 30 markets worldwide. To turn these insights into your market success story, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This episode of LATAM MedTech Insights dives deep into the most significant regulatory shift in the region's largest market: Brazil. We explore ANVISA's new regulations, RDC 751/2022 for medical devices and RDC 830/2023 for IVDs, which align Brazil's framework more closely with international standards like the EU MDR. This is a critical update for any MedTech company looking to enter or expand its footprint in Latin America. We unpack what this harmonization means in practical terms. Consider this: a medical device company with CE marking for its product previously faced a complex, 18-month process to reformat its entire technical dossier for Brazil. Today, that same dossier can be leveraged to gain market access in a fraction of the time and cost. This episode explains how you can capitalize on this change and avoid common pitfalls during the transition. Key Takeaways: * How does Brazil's new RDC 751/2022 fundamentally change the market entry strategy for your medical device? * What is the critical June 1, 2024 deadline for IVD manufacturers under RDC 830/2023 and what must be done? * Can your existing EU or FDA technical documentation be used for a submission in Brazil now? * How does Brazil's regulatory shift compare to changes happening in Mexico and Colombia? * What are the key differences between the old 'cadastro' system and the new 'notificação' pathway? * Why is having an expert local representative in Brazil more crucial than ever under these new rules? * What are the most common mistakes companies make when transitioning their legacy products to the new regulations? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, from initial strategy to post-market surveillance. To navigate the complexities of the LATAM market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we explore why a one-size-fits-all approach to entering the Latin American medical technology market is a recipe for failure. The region is not a monolith but a collection of unique countries, each with its own distinct regulatory, economic, and healthcare systems. Success depends on moving beyond surface-level data and leveraging deep market intelligence. We dissect how granular market briefs provide the critical insights needed to build a winning go-to-market strategy. We contrast the opportunities in a market like Colombia, which heavily relies on imports, with the complex regulatory hurdles of a giant like Brazil. This episode will show you how the right data can illuminate your path, save you from costly mistakes, and give you a decisive competitive advantage. A Tale of Two Markets: Imagine targeting Colombia, where an 80% import dependency for medical devices signals a ready-made demand for your product. Now, picture Brazil, where your market entry is halted before it begins because you were unaware of the mandatory pre-submission GMP inspection by ANVISA. This single regulatory detail could delay your launch by over a year and add tens of thousands to your budget. Which path would you rather take? Key Takeaways: * Why is treating LATAM as a single market the most common strategic error? * What does Colombia's 80% import dependency really mean for your sales strategy? * How can Brazil's ANVISA pre-registration requirements completely alter your budget and timeline? * Beyond market size, what are the most critical data points a market brief must contain? * How does deep market intelligence inform your choice between direct entry and a distributor model? * What hidden regulatory hurdles could derail your launch in promising markets? * How can you leverage existing international approvals to potentially fast-track your LATAM entry? * What economic indicators should you monitor that directly impact medical device reimbursement? At Pure Global, we transform this critical data into actionable strategy. We offer end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline your global market access. Stop guessing and start strategizing. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help you succeed in Latin America and beyond.

Brazil's MedTech market offers immense opportunity, but its regulatory body, ANVISA, demands flawless execution. A fragmented approach, where different teams handle registration and post-market compliance, often leads to costly delays and strategic dead ends. This episode explores why an integrated strategy is non-negotiable for success. We break down the four pillars of Brazilian MedTech regulation: correct device classification, meticulous technical documentation in Portuguese, the critical choice of a Brazil Registration Holder (BRH), and robust post-market surveillance. Learn how these elements are interconnected and why managing them under one expert team provides a significant competitive advantage in this complex market. **A cautionary tale:** Imagine spending over a year and thousands of dollars to prepare your device registration, only to discover that the distributor you appointed as your local representative (BRH) has decided to partner with a competitor. Because they legally own your registration license, you have completely lost market access and must start the entire process from scratch, giving your competition a two-year head start. **In this episode, you will learn:** * Why is Brazil's four-class risk system more nuanced than it appears? * What are the most common documentation mistakes that lead to ANVISA rejections? * How can the choice of your Brazil Registration Holder (BRH) make or break your entire LATAM strategy? * Are you truly in control of your device registration if your distributor is your BRH? * What specific post-market surveillance activities does ANVISA require beyond simple adverse event reporting? * Why is having a single, integrated team for registration and post-market support a competitive advantage in Brazil? * What is BGMP certification and why is it non-negotiable for higher-risk devices? At Pure Global, we offer end-to-end regulatory solutions for MedTech and IVD companies. Our integrated approach combines local Brazilian expertise with advanced AI tools to streamline market access, from initial strategy to post-market surveillance. Contact us to learn how our unified team can de-risk and accelerate your entry into the Brazilian market. Email us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we dive deep into the unique regulatory landscape of Colombia, a pivotal market for any device manufacturer looking to enter Latin America. We uncover how INVIMA's dual-track system offers a strategic gateway for MedTech companies that know how to leverage it. We explore the powerful "automatic registration" pathway for low-risk devices that can get your product to market and generating revenue faster than you think. We also break down the complexities and extended timelines associated with the rigorous pre-approval process for high-risk technologies, and how to plan for them effectively. A Case for Strategy: Imagine trying to launch your entire device portfolio, from simple monitors to complex implants, into a new continent at once. The pain point is the immense upfront cost and the years of waiting for approvals before seeing a single dollar in return. One company flipped this challenge on its head. They launched their Class I device in Colombia in just a few months, using the immediate cash flow to fund the lengthy, data-intensive registration for their groundbreaking Class III product. This is how a regulatory landscape becomes a competitive advantage. This episode's key takeaways: 1. What is Colombia's "automatic registration" and which specific devices qualify? 2. How can a fast-track for low-risk products actually fund your entire LATAM expansion? 3. What are the most common documentation pitfalls that lead to rejection in an "automatic" submission? 4. How do you prepare a technical dossier for a high-risk Class III device that satisfies INVIMA's stringent review? 5. Why is a staggered, portfolio-based market entry strategy essential for success in Colombia? 6. How does your Colombian approval act as a potential stepping stone for other LATAM markets? 7. What are the critical roles and responsibilities of a local Legal Representative in the INVIMA process? At Pure Global, we specialize in transforming complex regulatory landscapes into clear, actionable market access strategies. Our teams of local experts, powered by advanced AI and data tools, offer end-to-end solutions for MedTech and IVD companies. Whether you are navigating Colombia's INVIMA for the first time or expanding across the continent, we streamline your path to market. Ready to build your LATAM strategy? Contact us at info@pureglobal.com or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the complex process of medical device registration in Argentina. We provide a detailed guide on navigating the requirements of the national regulatory authority, ANMAT, from appointing a local registration holder to preparing a compliant technical dossier in Spanish. We break down the critical steps and common pitfalls that can lead to costly delays and rejections. Learn why your choice of a local partner can make or break your market access strategy and how your existing international approvals, like CE or FDA, fit into the Argentinian framework. We share a real-world case where a simple oversight in device grouping strategy tripled a company's registration costs and delayed market entry by a full year, highlighting the financial and strategic importance of local know-how. Key questions answered in this episode: - Why is selecting the right Argentina Registration Holder (ARH) your most critical first step? - What are the specific Spanish language requirements for your technical file that most companies miss? - How can a proper device family strategy cut your ANMAT submission costs and timeline? - What is the one common document error that causes the longest delays with ANMAT's review clock? - Are your existing CE or FDA approvals enough to guarantee a smooth registration in Argentina? - What are the realistic timelines you should expect for ANMAT approval for different device classes? - How can you avoid having your registration "held hostage" by a local commercial partner? At Pure Global, we provide end-to-end regulatory solutions for MedTech companies seeking to enter or expand in Latin America. Our local experts in Argentina, combined with our advanced AI tools, streamline the ANMAT registration process, from strategy and dossier preparation to post-market compliance. Let us be your dedicated partner in unlocking this key market. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Peru's MedTech market offers immense growth opportunities, but entry is strictly controlled by its regulatory authority, DIGEMID. A critical step for any foreign manufacturer is appointing a local representative, known as a Peru Registration Holder. This isn't just a formality—it's a foundational strategic decision that dictates your control over your own products in the country. In this episode, we explore why the common shortcut of letting a distributor hold your product registration can lead to significant business risks, including a complete loss of market access. We'll walk through the strategic advantages of appointing an independent, professional representative to ensure you maintain full control over your commercial strategy and long-term success in Peru. Here is a situation we explore: Imagine your medical device has been selling in Peru for two years. Your relationship with your distributor, who also holds your DIGEMID registration, has broken down. You decide to switch partners, only to discover the distributor refuses to transfer the registration. They legally own your access to the market. You are now faced with a devastating choice: stay with an underperforming partner or pull your product and start the costly, year-long registration process all over again. This is a real and preventable crisis. Key Takeaways: 1. What is the precise function of a "Peru Registration Holder" for DIGEMID? 2. Why is it a significant risk to let your distributor be your registration holder? 3. What are the legal implications of who owns your product registration in Peru? 4. How does an independent local representative provide crucial commercial flexibility? 5. What happens to your market access if your relationship with your distributor-holder ends? 6. What are the key steps in the DIGEMID registration process that a local representative handles? 7. How does having a dedicated representative help in navigating post-market surveillance in Peru? At Pure Global, we specialize in demystifying complex regulatory landscapes like Peru's. We provide independent, expert local representation, ensuring you retain full control over your assets while we handle the complexities of DIGEMID. Secure your market access and build a flexible, scalable LATAM strategy. Contact us to learn more at info@pureglobal.com or visit our website at https://pureglobal.com/.